09:43 AM EST, 02/27/2025 (MT Newswires) -- Xencor ( XNCR ) reported a Q4 net loss of $0.62 per diluted share, wider than its loss of $0.43 year earlier.

Analysts surveyed by FactSet expected a loss of $0.78.

Revenue for the quarter ended Dec. 31 was $52.8 million, compared with $51 million a year earlier.

Analysts surveyed by FactSet expected $20.4 million.

The clinical-stage biopharmaceutical company said it expects to end 2025 with cash, cash equivalents and marketable debt securities in a range of $535 million to $585 million, and to have cash to fund research, development programs and operations into 2028.

Price: 14.81, Change: +0.43, Percent Change: +2.99